US › Healthcare

Cellectis SA (CLLS)

US · Healthcare · Biotechnology

$2.77+0.73%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$5.8M
Revenue YoY
-45.6%
Net profit
$-17.8M
Profit YoY
+1.6%
EPS
$-0.18
EPS estimate
$-0.26
Net margin
-307.5%

EPS came in at -0.18 against a street estimate of -0.26 — a beat of 30.8%.

Key statistics

Market cap
$276.9M
Forward P/E
0.0
P/B
4.62
Book value
$0.82
EPS (TTM)
$-0.67
52-week high
$5.48
52-week low
$2.48
50-day MA
$3.05
200-day MA
$3.75
Beta
2.75

Analyst view

Analysts rate Cellectis SA a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $7.60.

Shareholding

Institutions
16.54%

Largest institutional holders

FundStake
B Group, Inc3.26%
UBS Asset Mgmt Americas Inc3.16%
Long Focus Capital Management, LLC2.73%
BlackRock Inc0.34%
Delaware Management Holdings Inc0.23%
Morgan Stanley - Brokerage Accounts0.09%
LPL Financial Corp0.08%
Susquehanna International Group, LLP0.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cellectis SA — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.